{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEET\t(Unaudited)\tOctober 1,\tDecember 31,\t(In millions except share and per share amounts)\t2022\t2021\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t2,919\t$\t4,477\tAccounts receivable, less allowances of $\t185\tand $\t150\t7,671\t7,977\tInventories\t5,722\t5,051\tContract assets, net\t1,248\t968\tOther current assets\t1,739\t1,640\tTotal current assets\t19,299\t20,113\tProperty, plant and equipment, net\t8,628\t8,333\tAcquisition-related intangible assets, net\t17,813\t20,113\tOther assets\t4,308\t4,640\tGoodwill\t40,488\t41,924\tTotal assets\t$\t90,536\t$\t95,123\tLiabilities, redeemable noncontrolling interest and equity\tCurrent liabilities:\tShort-term obligations and current maturities of long-term obligations\t$\t1,010\t$\t2,537\tAccounts payable\t2,471\t2,867\tAccrued payroll and employee benefits\t1,864\t2,427\tContract liabilities\t2,567\t2,655\tOther accrued expenses\t3,206\t2,950\tTotal current liabilities\t11,118\t13,436\tDeferred income taxes\t3,140\t3,837\tOther long-term liabilities\t4,401\t4,540\tLong-term obligations\t28,150\t32,333\tRedeemable noncontrolling interest\t119\t122\tEquity:\tThermo Fisher Scientific Inc. shareholders  equity:\tPreferred stock, $\t100\tpar value,\t50,000\tshares authorized;\tnone\tissued\t \t \tCommon stock, $\t1\tpar value,\t1,200,000,000\tshares authorized;\t440,352,770\tand\t439,154,741\tshares issued\t440\t439\tCapital in excess of par value\t16,596\t16,174\tRetained earnings\t40,452\t35,431\tTreasury stock at cost,\t48,157,213\tand\t44,720,112\tshares\t(\t11,011\t)\t(\t8,922\t)\tAccumulated other comprehensive items\t(\t2,928\t)\t(\t2,329\t)\tTotal Thermo Fisher Scientific Inc. shareholders  equity\t43,549\t40,793\tNoncontrolling interests\t59\t62\tTotal equity\t43,608\t40,855\tTotal liabilities, redeemable noncontrolling interest and equity\t$\t90,536\t$\t95,123\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3\tTHERMO FISHER SCIENTIFIC INC.\tCONDENSED CONSOLIDATED STATEMENT OF INCOME\t(Unaudited)\tThree months ended\tNine months ended\tOctober 1,\tOctober 2,\tOctober 1,\tOctober 2,\t(In millions except per share amounts)\t2022\t2021\t2022\t2021\tRevenues\tProduct revenues\t$\t6,583\t$\t7,360\t$\t21,603\t$\t22,430\tService revenues\t4,094\t1,970\t11,862\t6,079\tTotal revenues\t10,677\t9,330\t33,465\t28,509\tCosts and operating expenses:\tCost of product revenues\t3,494\t3,298\t10,565\t9,977\tCost of service revenues\t2,881\t1,381\t8,535\t4,148\tSelling, general and administrative expenses\t2,208\t2,004\t6,694\t5,729\tResearch and development expenses\t351\t351\t1,080\t1,014\tRestructuring and other costs\t33\t18\t59\t151\tTotal costs and operating expenses\t8,967\t7,052\t26,933\t21,019\tOperating income\t1,710\t2,278\t6,532\t7,490\tInterest income\t68\t9\t122\t32\tInterest expense\t(\t173\t)\t(\t128\t)\t(\t457\t)\t(\t375\t)\tOther income/(expense)\t(\t4\t)\t18\t(\t139\t)\t(\t168\t)\tIncome before income taxes\t1,601\t2,177\t6,058\t6,979\tProvision for income taxes\t(\t31\t)\t(\t271\t)\t(\t530\t)\t(\t906\t)\tEquity in earnings/(losses) of unconsolidated entities\t(\t72\t)\t(\t3\t)\t(\t142\t)\t(\t4\t)\tNet income\t1,498\t1,903\t5,386\t6,069\tLess: net income attributable to noncontro"
        ],
        "timestamp": "2025-01-21_09-41-32"
    }
}